Header Logo

Connection

John Somberg to Anti-Arrhythmia Agents

Back to Details
This is a "connection" page, showing publications John Somberg has written about Anti-Arrhythmia Agents.
John Somberg
Connection Strength
7.039
Anti-Arrhythmia Agents
  1. The Bretylium Saga: A Novel "Old Drug" for Cardiac Resuscitation. Am J Cardiol. 2020 05 15; 125(10):1596-1598.
    View in: PubMed
    Score: 0.655
  2. QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol. Cardiology. 2010; 116(3):219-25.
    View in: PubMed
    Score: 0.337
  3. Developing a safe intravenous sotalol dosing regimen. Am J Ther. 2010 Jul-Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.335
  4. Flecainide: safety and efficacy. Cardiology. 2008; 111(2):82.
    View in: PubMed
    Score: 0.286
  5. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology. 2008; 110(3):145-52.
    View in: PubMed
    Score: 0.280
  6. Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. Cardiology. 2008; 110(3):209-16.
    View in: PubMed
    Score: 0.280
  7. The effects of quinidine and its chiral isolates on erg-1sm potassium current and correlation with gastrointestinal augmentation. Am J Ther. 2007 May-Jun; 14(3):269-76.
    View in: PubMed
    Score: 0.269
  8. The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Cardiology. 2007; 108(1):18-27.
    View in: PubMed
    Score: 0.257
  9. Letter from Konstantinos P. Letsas et al. - invited editorial comment. Cardiology. 2006; 105(3):148.
    View in: PubMed
    Score: 0.246
  10. The effect of magnesium sulfate on action potential duration and cardiac arrhythmias. Am J Ther. 2005 May-Jun; 12(3):218-22.
    View in: PubMed
    Score: 0.234
  11. The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther. 2005 Mar; 10(1):67-76.
    View in: PubMed
    Score: 0.231
  12. Pharmacology and toxicology of a new aqueous formulation of intravenous amiodarone (Amio-Aqueous) compared with Cordarone IV. Am J Ther. 2005 Jan-Feb; 12(1):9-16.
    View in: PubMed
    Score: 0.229
  13. Lack of a hypotensive effect with rapid administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004 Mar 01; 93(5):576-81.
    View in: PubMed
    Score: 0.216
  14. The quest for an aqueous amiodarone. Am J Ther. 2003 Nov-Dec; 10(6):458-61.
    View in: PubMed
    Score: 0.211
  15. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2002 Nov 01; 90(9):964-8.
    View in: PubMed
    Score: 0.197
  16. Arrhythmia therapy. Am J Ther. 2002 Nov-Dec; 9(6):537-42.
    View in: PubMed
    Score: 0.197
  17. Intravenous lidocaine versus intravenous amiodarone (in a new aqueous formulation) for incessant ventricular tachycardia. Am J Cardiol. 2002 Oct 15; 90(8):853-9.
    View in: PubMed
    Score: 0.196
  18. Intravenous Sotalol for the Treatment of Ventricular Dysrhythmias in an Infant on Extracorporeal Membrane Oxygenation. Pediatr Cardiol. 2020 Feb; 41(2):418-422.
    View in: PubMed
    Score: 0.160
  19. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology. 2017; 136(1):52-60.
    View in: PubMed
    Score: 0.128
  20. Adverse Reactions of Amiodarone on the Thyroid. Cardiology. 2016; 134(3):364-5.
    View in: PubMed
    Score: 0.125
  21. Proarrhythmia: definition, risk factors, causes, treatment, and controversies. Am Heart J. 1994 Sep; 128(3):575-85.
    View in: PubMed
    Score: 0.112
  22. New advances and new questions in cardiovascular therapeutics. Am J Ther. 2009 Sep-Oct; 16(5):375-7.
    View in: PubMed
    Score: 0.079
  23. Encainide: a new and potent antiarrhythmic. Am Heart J. 1987 Oct; 114(4 Pt 1):826-35.
    View in: PubMed
    Score: 0.069
  24. The antiarrhythmic effects of d-sotalol. Am Heart J. 1987 Sep; 114(3):539-44.
    View in: PubMed
    Score: 0.069
  25. Evaluation of dosing interval and optimum dose of cibenzoline. J Clin Pharmacol. 1987 Sep; 27(9):666-72.
    View in: PubMed
    Score: 0.069
  26. Comparative efficacy of pirmenol and procainamide in a drug-resistant population with ventricular tachycardia. J Clin Pharmacol. 1987 Jul; 27(7):481-6.
    View in: PubMed
    Score: 0.068
  27. Refractory ventricular tachycardia with flecainide. Am Heart J. 1986 Jul; 112(1):174-5.
    View in: PubMed
    Score: 0.063
  28. The treatment of ventricular rhythm disturbances. Am Heart J. 1986 Jun; 111(6):1162-76.
    View in: PubMed
    Score: 0.063
  29. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Am Heart J. 1986 Apr; 111(4):661-6.
    View in: PubMed
    Score: 0.062
  30. Antiarrhythmic drug efficacy at electrophysiology testing: predictive effectiveness of procainamide and flecainide. Am Heart J. 1986 Apr; 111(4):632-8.
    View in: PubMed
    Score: 0.062
  31. A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther. 2005 Jul-Aug; 12(4):328-36.
    View in: PubMed
    Score: 0.059
  32. The arrhythmogenicity of antiarrhythmic agents. Am Heart J. 1985 May; 109(5 Pt 1):1090-7.
    View in: PubMed
    Score: 0.058
  33. Antiarrhythmic effects of cibenzoline. Am Heart J. 1985 Apr; 109(4):827-33.
    View in: PubMed
    Score: 0.058
  34. Therapy for late post infarction ventricular tachycardia. Angiology. 1985 Mar; 36(3):181-90.
    View in: PubMed
    Score: 0.058
  35. Antiarrhythmic drug therapy. Recent advances and current status. Cardiology. 1985; 72(5-6):329-48.
    View in: PubMed
    Score: 0.057
  36. Prolongation of QT interval and antiarrhythmic action of bepridil. Am Heart J. 1985 Jan; 109(1):19-27.
    View in: PubMed
    Score: 0.057
  37. Long term lorcainide therapy guided by electrophysiology studies. Acta Cardiol. 1985; 40(6):621-36.
    View in: PubMed
    Score: 0.057
  38. Flecainide: long-term treatment using a reduced dosing schedule. Am J Cardiol. 1985 Jan 01; 55(1):79-83.
    View in: PubMed
    Score: 0.057
  39. The effect of bepridil, verapamil, and quinidine in the prevention of ventricular tachycardia induced by programmed electrical stimulation in the digitalized dog. Am Heart J. 1984 Nov; 108(5):1236-43.
    View in: PubMed
    Score: 0.057
  40. The efficacy of cibenzoline in preventing PES induction of ventricular tachycardia in the dog. J Clin Pharmacol. 1984 Oct; 24(10):466-72.
    View in: PubMed
    Score: 0.056
  41. New directions in antiarrhythmic drug therapy. Am J Cardiol. 1984 Aug 13; 54(4):8B-17B.
    View in: PubMed
    Score: 0.056
  42. New directions in antiarrhythmic drug therapy: the development of a promising new agent, lorcainide. Am J Cardiol. 1984 Aug 13; 54(4):1B.
    View in: PubMed
    Score: 0.056
  43. Lorcainide therapy for the high-risk patient post myocardial infarction. Am J Cardiol. 1984 Aug 13; 54(4):37B-42B.
    View in: PubMed
    Score: 0.056
  44. Evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):43B-48B.
    View in: PubMed
    Score: 0.056
  45. Comparison of noninvasive arrhythmia induction techniques with electrophysiologic studies and evaluation of lorcainide in patients with symptomatic ventricular tachycardia. Am J Cardiol. 1984 Aug 13; 54(4):49B-54B.
    View in: PubMed
    Score: 0.056
  46. New approaches to drug selection and serial drug testing. J Clin Pharmacol. 1984 Jul; 24(7):320-7.
    View in: PubMed
    Score: 0.055
  47. Pacing termination of ventricular tachycardia: influence of antiarrhythmic-slowed ectopic rate. Am Heart J. 1984 Apr; 107(4):638-43.
    View in: PubMed
    Score: 0.054
  48. Rapid determination of partition coefficients between n-octanol/water for cardiovascular therapies. Am J Ther. 2002 Jan-Feb; 9(1):19-24.
    View in: PubMed
    Score: 0.046
  49. Histamine antagonists as antiarrhythmic agents in ouabain cardiotoxicity in the cat. J Pharmacol Exp Ther. 1980 Aug; 214(2):375-80.
    View in: PubMed
    Score: 0.042
  50. Inhibition of Human Ether-A-Go-Go-Related Gene (hERG) Potassium Current by the Novel Sotalol Analogue, Soestalol. JACC Clin Electrophysiol. 2020 07; 6(7):756-759.
    View in: PubMed
    Score: 0.042
  51. The antiarrhythmic effects of quinidine and propranolol in the ouabain-intoxicated spinally transected cat. Eur J Pharmacol. 1979 Feb 15; 54(1-2):161-6.
    View in: PubMed
    Score: 0.038
  52. Successful heart failure therapy is effective antiarrhythmia therapy. Am Heart J. 1996 May; 131(5):1048-50.
    View in: PubMed
    Score: 0.031
  53. Electrophysiology of Ethmozine (moricizine HCl) for ventricular tachycardia. Am J Cardiol. 1987 Oct 16; 60(11):67F-72F.
    View in: PubMed
    Score: 0.017
  54. Supraventricular tachyarrhythmias: their evaluation and therapy. Am Heart J. 1986 Jun; 111(6):1150-61.
    View in: PubMed
    Score: 0.016
  55. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias. J Am Coll Cardiol. 1986 Jan; 7(1):9-16.
    View in: PubMed
    Score: 0.015
  56. The clinical significance of polymorphic ventricular tachycardia provoked at electrophysiologic testing. Am Heart J. 1985 Jul; 110(1 Pt 1):17-24.
    View in: PubMed
    Score: 0.015
  57. Pharmacokinetics of oral cibenzoline in arrhythmia patients. Clin Pharmacokinet. 1985 Mar-Apr; 10(2):178-86.
    View in: PubMed
    Score: 0.014
  58. Prolonged repolarization: a historical perspective. Am Heart J. 1985 Feb; 109(2):395-8.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.